Home Alzheimer’s Disease Clayton Lau, MD, on How COVID-19 Has and Will Continue to Impact...

Clayton Lau, MD, on How COVID-19 Has and Will Continue to Impact Cancer Care

The chief of urologic oncology at City of Hope spoke about how the COVID-19 pandemic has altered the way he cares for patients with cancer as well as how he believes it will continue to impact cancer prevention, detection, and treatment moving forward.

Numerous studies have been published recently highlighting the impact that the coronavirus disease 2019 (COVID-19) pandemic has had on cancer prevention, detection, and treatment.

Though it is not yet known what the full impact of the pandemic will be, these studies emphasize concerns that delays in care could result in a rise of late-stage diagnoses and cancer deaths in the coming years.

In an interview with CancerNetwork®, Clayton Lau, MD, chief of urologic oncology at City of Hope, discussed how COVID-19 has affected his ability to treat patients with cancer as well as how he believes the pandemic will continue to shape cancer…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments